Athera Biotechnologies AB, of Stockholm, said it closed a new share issue, raising SEK55 million (US$5.69 million). The new capital will be used for a phase II study that enrolled the first patient in April. The study is planned to run at 11 hospitals and includes myocardial infarction patients with high risk to develop heart failure, who will receive either a single dose of the antibody ATH-3G10 or placebo.